Edgewise Therapeutics, Inc.(EWTX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

EWTX Edgewise Therapeutics, Inc.

Trading 09-24 15:22:25 EDT

41.05

+0.00

-0.01%

High41.94	Low39.74	Vol854.61K
Open40.97	D1 Closing41.05	Amplitude5.37%
Mkt Cap4.46B	Tradable Cap3.62B	Total Shares108.60M
T/O34.75M	T/O Rate0.97%	Tradable Shares88.17M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"EWTX","market":"US","secType":"STK","nameCN":"Edgewise Therapeutics, Inc.","latestPrice":41.045,"timestamp":1790277743467,"preClose":41.05,"halted":0,"volume":854609,"delay":0,"changeRate":-0.00012180267965884172,"floatShares":88170878,"shares":108604129,"eps":-1.850165,"marketStatus":"Trading","change":-0.005,"latestTime":"09-24 15:22:25 EDT","open":40.97,"high":41.94,"low":39.735,"amount":34745741.542183,"amplitude":0.053715,"askPrice":41.06,"askSize":247,"bidPrice":41.03,"bidSize":436,"shortable":0,"etf":0,"ttmEps":-1.850165,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1790280000000},"marketStatusCode":2,"adr":0,"listingDate":1616731200000,"exchange":"NASDAQ","adjPreClose":41.05,"preHourTrading":{"tag":"盘前","latestPrice":41.12,"preClose":41.05,"latestTime":"09:28 EDT","volume":1633,"amount":67153.847569,"timestamp":1790256514979,"change":0.07,"changeRate":0.001705,"amplitude":0.060901},"postHourTrading":{"tag":"盘后","latestPrice":41.05,"preClose":41.05,"latestTime":"19:30 EDT","volume":2260,"amount":92762.1,"timestamp":1790206202428,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.45939,"impliedVol":0.6721,"impliedVolPercentile":0.4263},"requestUrl":"/m/hq/s/EWTX","defaultTab":"news","newsList":[{"id":"2669380384","title":"Edgewise Therapeutics Down over 9%, on Pace for Largest Percent Decrease Since December 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2669380384","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669380384?lang=en_us&edition=fundamental","pubTime":"2026-09-24 01:55","pubTimestamp":1790186100,"startTime":"0","endTime":"0","summary":"Edgewise Therapeutics, Inc.  is currently at $40.30, down $4.21 or 9.45%--Would be lowest close since Aug. 3, 2026, when it closed at $38.38--On pace for largest percent decrease since Dec. 22, 2025, when it fell 18.04%--Currently down four consecutive days; down 14.14% over this period--Longest losing streak since July 1, 2026, when it fell for five straight trading days--Worst four day stretch since the four days ending July 16, 2026, when it fell 15.9%--Down 3.51% month-to-date; on pace for worst month since July 2026, when it fell 5.41%--Up 62.42% year-to-date--Down 16.64% from its all-time closing high of $48.35 on July 9, 2026--Up 142.95% from 52 weeks ago , when it closed at $16.59--Down 16.64% from its 52-week closing high of $48.35 on July 9, 2026--Up 174.18% from its 52-week closing low of $14.70 on Oct. 14, 2025--Traded as low as $40.01; lowest intraday level since Aug. 3, 2026, when it hit $36.88--Down 10.12% at today's intraday low; largest intraday percent decrease since ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EWTX","BK4539","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669876844","title":"Edgewise's EDG-7500 Mechanism Lends Confidence, RBC Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2669876844","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669876844?lang=en_us&edition=fundamental","pubTime":"2026-09-23 23:41","pubTimestamp":1790178065,"startTime":"0","endTime":"0","summary":"Edgewise Therapeutics'  EDG-7500 mechanism reveal accounts for strong clinical showing, lending confidence ahead  of phase 3 trial design, RBC said in a Tuesday note.Earlier, the company unveiled a differentiated mechanism of action of its cardiac sarcomere modulator EDG-7500.The mechanism that targets the Regulatory Light Chain has shown in preclinical models to improve cardiac relaxation while preserving systolic function and cardiac reserve, Edgewise said.\"We think the mechanism makes sense of the differentiated clinical profile to date,\" RBC analysts said.\"While the stock is unlikely to move significantly today, we came away confident in EWTX's opportunity to differentiate in HCM from CMIs,\" they added. HCM refers to hypertrophic cardiomyopathy, and CMI to cardiac myosin inhibitors.RBC maintained its outperform rating and $59 price target.Price: 41.26, Change: -3.25, Percent Change: -7.30","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4007","BK4539","EWTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669882494","title":"Edgewise Therapeutics (EWTX) Gets a Buy from RBC Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2669882494","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669882494?lang=en_us&edition=fundamental","pubTime":"2026-09-23 19:35","pubTimestamp":1790163342,"startTime":"0","endTime":"0","summary":"In a report released yesterday, Leonid Timashev from RBC Capital maintained a Buy rating on Edgewise Therapeutics, with a price target of $59.00. T...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/edgewise-therapeutics-ewtx-gets-a-buy-from-rbc-capital-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/edgewise-therapeutics-ewtx-gets-a-buy-from-rbc-capital-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0029864427.USD","GSIB","LU1267930573.SGD","EWTX","BK4007","BK4539","LU0128525929.USD","BK4207","LU0708994859.HKD","LU0310800379.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669146649","title":"Edgewise Therapeutics Details Preclinical Profile of EDG-7500 Cardiac Sarcomere Modulator in Hypertrophic Cardiomyopathy","url":"https://stock-news.laohu8.com/highlight/detail?id=2669146649","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669146649?lang=en_us&edition=fundamental","pubTime":"2026-09-22 19:01","pubTimestamp":1790074893,"startTime":"0","endTime":"0","summary":"Edgewise Therapeutics details preclinical profile of EDG-7500 cardiac sarcomere modulator in hypertrophic cardiomyopathyEdgewise Therapeutics outlined the preclinical profile for EDG-7500, a first-in-","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260922:nNDL3rsYMz:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EWTX","BK4539","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669150816","title":"Edgewise Therapeutics Price Target Raised to $57.00/Share from $45.00 by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2669150816","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669150816?lang=en_us&edition=fundamental","pubTime":"2026-09-21 18:53","pubTimestamp":1789987980,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/EWTX/analyst-ratings","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EWTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669155576","title":"US Research Roundup-eBay, Sunbelt Rentals, T-Mobile","url":"https://stock-news.laohu8.com/highlight/detail?id=2669155576","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669155576?lang=en_us&edition=fundamental","pubTime":"2026-09-21 15:41","pubTimestamp":1789976490,"startTime":"0","endTime":"0","summary":"US RESEARCH ROUNDUP-eBay, Sunbelt Rentals, T-MobileSept 21 (Reuters)-Wall Street securities analysts revised their ratings and price targets on several US-listed companies, including eBay, Sunbelt Ren","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260921:nL4N45D0ES:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HAKY","OKTX","BKH","MLPA","OKTG","PAA","PAGP","LU0109394709.USD","TMUS","TTMI","BK4504","TTMX","BLSM","ONLN","THNR","MCHB","AMZA","CL","SUNB","LU0251131958.USD","SPAM","EMLP","PKB","GOSS","STBQ","EWTX","EBAY","FOUR","MTZ","IQMX","LU1064131342.USD","SRRK","THO","ARHS","LU2095319765.USD","LU2322448957.HKD","LU1201861249.SGD","AIRR","NBIX","OKTA","BK4528","AMLP","BUG","HUBS","IBRN","CLIX","CDW","AMRZ","PSWD","IHAK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664881914","title":"Edgewise Therapeutics Grants Inducement Equity Awards Covering 31,501 Shares to New Hires","url":"https://stock-news.laohu8.com/highlight/detail?id=2664881914","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664881914?lang=en_us&edition=fundamental","pubTime":"2026-09-02 20:00","pubTimestamp":1788350425,"startTime":"0","endTime":"0","summary":"Edgewise Therapeutics grants inducement equity awards covering 31,501 shares to new hiresEdgewise Therapeutics granted inducement equity awards to four new non-executive employees on Aug. 31, 2026.Sto","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260902:nNDL6yP9rz:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4539","EWTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664191808","title":"Edgewise Therapeutics Reports Inducement Grants as Permitted by the NASDAQ Listing Rules","url":"https://stock-news.laohu8.com/highlight/detail?id=2664191808","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664191808?lang=en_us&edition=fundamental","pubTime":"2026-09-02 20:00","pubTimestamp":1788350403,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260902:nTUA1SNHZZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["EWTX","BK4007","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664985977","title":"Goldman Sachs Sticks to Their Hold Rating for Edgewise Therapeutics (EWTX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2664985977","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664985977?lang=en_us&edition=fundamental","pubTime":"2026-09-01 20:36","pubTimestamp":1788266184,"startTime":"0","endTime":"0","summary":"In a report released yesterday, Paul Choi from Goldman Sachs maintained a Hold rating on Edgewise Therapeutics, with a price target of $36.00. The ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/goldman-sachs-sticks-to-their-hold-rating-for-edgewise-therapeutics-ewtx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/goldman-sachs-sticks-to-their-hold-rating-for-edgewise-therapeutics-ewtx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["EWTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663026580","title":"Edgewise Therapeutics (EWTX) Receives a Buy from RBC Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2663026580","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663026580?lang=en_us&edition=fundamental","pubTime":"2026-08-31 09:45","pubTimestamp":1788140740,"startTime":"0","endTime":"0","summary":"RBC Capital analyst Leonid Timashev maintained a Buy rating on Edgewise Therapeutics on August 27 and set a price target of $59.00. The company’s s...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/edgewise-therapeutics-ewtx-receives-a-buy-from-rbc-capital-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/edgewise-therapeutics-ewtx-receives-a-buy-from-rbc-capital-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["EWTX","BK4539","LU1267930573.SGD","LU0708994859.HKD","LU0029864427.USD","LU0128525929.USD","BK4207","LU0310800379.SGD","GSIB","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661276378","title":"Edgewise Says Phase 2 Cirrus-HCM Trial Shows Positive Top-Line Data for EDG-7500 in Hypertrophic Cardiomyopathy","url":"https://stock-news.laohu8.com/highlight/detail?id=2661276378","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661276378?lang=en_us&edition=fundamental","pubTime":"2026-08-24 20:02","pubTimestamp":1787572938,"startTime":"0","endTime":"0","summary":"Edgewise says Phase 2 CIRRUS-HCM trial shows positive top-line data for EDG-7500 in hypertrophic cardiomyopathyEdgewise Therapeutics flagged positive top-line results from its 12-week Phase 2 CIRRUS-H","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260824:nNDL5MQ07j:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4539","EWTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661252375","title":"Egetis Bolsters Finances and IP as Emcitate Nears Key FDA Decision","url":"https://stock-news.laohu8.com/highlight/detail?id=2661252375","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661252375?lang=en_us&edition=fundamental","pubTime":"2026-08-21 13:33","pubTimestamp":1787290381,"startTime":"0","endTime":"0","summary":"Egetis Therapeutics AB ( ($SE:EGTX) ) has provided an update. Egetis Therapeutics reported second-quarter 2026 net revenue of SEK 17.4 million from...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/egetis-bolsters-finances-and-ip-as-emcitate-nears-key-fda-decision?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/egetis-bolsters-finances-and-ip-as-emcitate-nears-key-fda-decision?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","BK4539","EWTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661239730","title":"Edgewise Therapeutics Price Target Raised to $60.00/Share from $53.00 by JP Morgan","url":"https://stock-news.laohu8.com/highlight/detail?id=2661239730","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661239730?lang=en_us&edition=fundamental","pubTime":"2026-08-21 02:05","pubTimestamp":1787249100,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/EWTX/analyst-ratings","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EWTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660289321","title":"Edgewise Therapeutics price target raised to $60 from $53 at JPMorgan","url":"https://stock-news.laohu8.com/highlight/detail?id=2660289321","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660289321?lang=en_us&edition=fundamental","pubTime":"2026-08-20 19:20","pubTimestamp":1787224854,"startTime":"0","endTime":"0","summary":"JPMorgan raised the firm’s price target on Edgewise Therapeutics (EWTX) to $60 from $53 and keeps an Overweight rating on the shares. The firm upda...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/edgewise-therapeutics-price-target-raised-to-60-from-53-at-jpmorgan-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/edgewise-therapeutics-price-target-raised-to-60-from-53-at-jpmorgan-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["EWTX","PRTO","PGF"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660406372","title":"Edgewise Therapeutics (EWTX) Is Up 6.6% After Wider Q2 Losses Highlight Rising Spend - Has The Bull Case Changed?","url":"https://stock-news.laohu8.com/highlight/detail?id=2660406372","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660406372?lang=en_us&edition=fundamental","pubTime":"2026-08-20 13:28","pubTimestamp":1787203731,"startTime":"0","endTime":"0","summary":"Edgewise Therapeutics, Inc. reported second-quarter 2026 results showing a net loss of US$57.33 million and basic loss per share of US$0.53, with first-half 2026 net loss reaching US$106.34 million and loss per share of US$0.99, both higher than the same periods a year earlier.\nThe widening losses highlight the company’s increasing spending relative to its current revenue base, which will be central to assessing its financial trajectory and funding needs.\nNext, we will examine how the...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ewtx/edgewise-therapeutics/news/edgewise-therapeutics-ewtx-is-up-66-after-wider-q2-losses-hi","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ewtx/edgewise-therapeutics/news/edgewise-therapeutics-ewtx-is-up-66-after-wider-q2-losses-hi","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4539","BK4007","EWTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660096101","title":"Edgewise Therapeutics (EWTX) Reports Wider Losses On A Valuation That Still Looks Rich","url":"https://stock-news.laohu8.com/highlight/detail?id=2660096101","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660096101?lang=en_us&edition=fundamental","pubTime":"2026-08-17 09:25","pubTimestamp":1786929928,"startTime":"0","endTime":"0","summary":"Edgewise Therapeutics (EWTX) recently reported second quarter 2026 results that showed a wider net loss of $57.33 million and a basic loss per share of $0.53, compared with the prior year period.\nSee our latest analysis for Edgewise Therapeutics.\nDespite the wider loss, Edgewise Therapeutics shares have shown strong momentum, with a 30 day share price return of 11.09% and an 85.98% year to date share price return. The 1 year total shareholder return of 212.16% and 3 year total shareholder...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ewtx/edgewise-therapeutics/news/edgewise-therapeutics-ewtx-reports-wider-losses-on-a-valuati","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ewtx/edgewise-therapeutics/news/edgewise-therapeutics-ewtx-reports-wider-losses-on-a-valuati","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4539","BK4007","EWTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659121925","title":"Edgewise Therapeutics CMO Joanne M. Donovan Disposes of USD 411,192 in Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2659121925","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659121925?lang=en_us&edition=fundamental","pubTime":"2026-08-15 04:57","pubTimestamp":1786741070,"startTime":"0","endTime":"0","summary":"Edgewise Therapeutics CMO Joanne M. Donovan disposes of USD 411,192 in common sharesEdgewise Therapeutics CMO Joanne M. Donovan reported RSU vesting on Aug. 12, 2026, adding 12,812 common shares.Sold ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260814:nNDL45dswq:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Edgewise Therapeutics CMO Joanne M. Donovan Disposes of USD 411,192 in Common Shares","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","EWTX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658917581","title":"Edgewise Therapeutics is Maintained at Neutral by Goldman Sachs","url":"https://stock-news.laohu8.com/highlight/detail?id=2658917581","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658917581?lang=en_us&edition=fundamental","pubTime":"2026-08-12 02:02","pubTimestamp":1786471320,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/EWTX/analyst-ratings","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EWTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658575991","title":"Edgewise Therapeutics price target raised to $36 from $32 at Goldman Sachs","url":"https://stock-news.laohu8.com/highlight/detail?id=2658575991","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658575991?lang=en_us&edition=fundamental","pubTime":"2026-08-11 18:15","pubTimestamp":1786443327,"startTime":"0","endTime":"0","summary":"Goldman Sachs raised the firm’s price target on Edgewise Therapeutics (EWTX) to $36 from $32 and keeps a Neutral rating on the shares. Published fi...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/edgewise-therapeutics-price-target-raised-to-36-from-32-at-goldman-sachs-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/edgewise-therapeutics-price-target-raised-to-36-from-32-at-goldman-sachs-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["EWTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657614018","title":"Wedbush Adjusts Pt on Edgewise Therapeutics to $53 From $52, Maintains Outperform Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2657614018","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657614018?lang=en_us&edition=fundamental","pubTime":"2026-08-07 18:08","pubTimestamp":1786097303,"startTime":"0","endTime":"0","summary":"Edgewise Therapeutics (EWTX) has an average rating of buy and mean price target of $50.46, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from maj","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["EWTX"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.edgewisetx.com","stockEarnings":[{"period":"1week","weight":-0.0966},{"period":"1month","weight":-0.0821},{"period":"3month","weight":-0.0154},{"period":"6month","weight":0.3311},{"period":"1year","weight":1.7203},{"period":"ytd","weight":0.6542}],"compareEarnings":[{"period":"1week","weight":0.0182},{"period":"1month","weight":0.0057},{"period":"3month","weight":0.0456},{"period":"6month","weight":0.2109},{"period":"1year","weight":0.1577},{"period":"ytd","weight":0.126}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company also develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders. In addition, it develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. The Company was incorporated in 2017 and is headquartered in Boulder, Colorado.","yearOnYearQuotes":[{"month":1,"riseRate":0.8,"avgChangeRate":0.169596},{"month":2,"riseRate":0.2,"avgChangeRate":-0.053086},{"month":3,"riseRate":0.4,"avgChangeRate":-0.097717},{"month":4,"riseRate":0.166667,"avgChangeRate":-0.044897},{"month":5,"riseRate":0.5,"avgChangeRate":-0.020981},{"month":6,"riseRate":0.5,"avgChangeRate":-0.010487},{"month":7,"riseRate":0.333333,"avgChangeRate":-0.007411},{"month":8,"riseRate":0.666667,"avgChangeRate":-0.000236},{"month":9,"riseRate":0.5,"avgChangeRate":0.079586},{"month":10,"riseRate":0.6,"avgChangeRate":0.092429},{"month":11,"riseRate":0.4,"avgChangeRate":0.07088},{"month":12,"riseRate":0.2,"avgChangeRate":0.087485}],"exchange":"NASDAQ","name":"Edgewise Therapeutics, Inc.","nameEN":"Edgewise Therapeutics, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Edgewise Therapeutics, Inc.(EWTX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Edgewise Therapeutics, Inc.(EWTX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Edgewise Therapeutics, Inc.,EWTX,Edgewise Therapeutics, Inc.股票,Edgewise Therapeutics, Inc.股票老虎,Edgewise Therapeutics, Inc.股票老虎国际,Edgewise Therapeutics, Inc.行情,Edgewise Therapeutics, Inc.股票行情,Edgewise Therapeutics, Inc.股价,Edgewise Therapeutics, Inc.股市,Edgewise Therapeutics, Inc.股票价格,Edgewise Therapeutics, Inc.股票交易,Edgewise Therapeutics, Inc.股票购买,Edgewise Therapeutics, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Edgewise Therapeutics, Inc.(EWTX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Edgewise Therapeutics, Inc.(EWTX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction